MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE - Generic Drug Details

What are the generic drug sources for magnesium sulfate; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium phosphate and what is the scope of patent protection?

Magnesium sulfate; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium phosphate is the generic ingredient in two branded drugs marketed by Baxter Hlthcare and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

US Patents:	0
Tradenames:	2
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
DailyMed Link:	MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE at DailyMed

Pharmacology for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

Drug Class	Calculi Dissolution Agent Osmotic Laxative Potassium Salt
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

Anatomical Therapeutic Chemical (ATC) Classes for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

A06AD	Osmotically acting laxatives
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

A06AD	Osmotically acting laxatives
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

A06AG	Enemas
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

A12BA	Potassium
A12B	POTASSIUM
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CA	Sodium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CC	Magnesium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05CB	Salt solutions
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

V03AG	Drugs for treatment of hypercalcemia
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

V04CC	Tests for bile duct patency
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	TIS-U-SOL IN PLASTIC CONTAINER	magnesium sulfate; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium phosphate	SOLUTION;IRRIGATION	018336-001	Approved Prior to Jan 1, 1982	AT	RX	No	No
Baxter Hlthcare	TIS-U-SOL	magnesium sulfate; potassium chloride; potassium phosphate, monobasic; sodium chloride; sodium phosphate	SOLUTION;IRRIGATION	018508-001	Feb 19, 1982	AT	RX	No	No

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE Market Analysis and Financial Projection

Last updated: February 15, 2026

What Are the Current Market Dynamics for Magnesium Sulfate, Potassium Chloride, Potassium Phosphate, Monobasic, Sodium Chloride, and Sodium Phosphate?

The global pharmaceutical market for these inorganic salts is driven by their extensive use in clinical, industrial, and consumer applications. Market size is influenced by clinical demand, manufacturing capacity, regulatory environment, and regional healthcare spending.

Major markets include North America, Europe, Asia-Pacific, Latin America, and the Middle East. North America maintains a leading position, supported by high healthcare expenditure, advanced infrastructure, and extensive pharmaceutical R&D. The Asia-Pacific region shows fastest growth owing to expanding healthcare coverage, increasing manufacturing facilities, and rising incidence of chronic diseases.

Clinical applications dominate revenue streams, with saline solutions and electrolyte replenishment accounting for significant segments. Industrial uses in food processing and water treatment also influence market volume.

How Has the Market for These Electrolytes Evolved Recently?

The market has experienced steady growth over the past five years, averaging compound annual growth rates (CAGR) ranging from 3% to 6%. The COVID-19 pandemic caused temporary disruptions in supply chains but increased global demand for electrolyte products due to widespread need for IV therapies in hospital settings.

Increases in chronic conditions like hypertension, heart failure, and electrolyte imbalance promote ongoing demand for magnesium sulfate and potassium-based products. Regulatory approvals for new drug formulations incorporating these salts have contributed to market expansion.

Innovation focuses on enhanced bioavailability formulations, new delivery methods, and sustainable manufacturing practices. There is also a growing trend of sourcing raw materials from environmentally sustainable suppliers.

What Are the Key Factors Influencing Market Trajectory?

1. Regulatory Environment: FDA, EMA, and other health authorities enforce strict quality standards. Approval processes impact new formulations.

2. Manufacturing Capacity & Supply Chain: Concentrated markets with few producers could face supply shortages. Raw material sourcing is affected by geopolitical factors.

3. Pricing and Reimbursement Policies: Payment models influence hospital procurement. Reimbursement rates for electrolyte therapy impact revenue.

4. Technological Innovation: Development of sustained-release formulations boosting clinical efficacy impacts future growth.

5. Emerging Markets: Increased healthcare spending and infrastructure in Asia-Pacific countries expand market access.

6. Environmental Regulations: Sustainability requirements influence manufacturing costs and raw material sourcing.

What Are the Financial Trends and Projections?

Compound	2022 Revenue (USD Billion)	2027 Projected Revenue (USD Billion)	CAGR (%)	Main Market Share (Region)	Key Drivers
Magnesium sulfate	0.85	1.15	6.4	North America, Europe	Obstetric and eclampsia therapy, ED management
Potassium chloride	1.2	1.52	4.4	Asia-Pacific, North America	Electrolyte replenishment, dialysis
Potassium phosphate, monobasic	0.4	0.55	6.1	North America	Nutritional therapy, renal care
Sodium chloride	2.1	2.9	7.5	North America, Asia-Pacific	Saline solutions, industrial use
Sodium phosphate	0.3	0.4	6.0	Europe, Asia-Pacific	Buffering agents, laxatives

The market is expected to grow steadily, driven primarily by saline and electrolyte therapies. Future growth may accelerate due to innovations like delivery system improvements and increased use in emerging markets.

What Are the Challenges and Risks?

1. Market Concentration: A small number of large producers control raw material supply, risking price volatility and shortages.

2. Regulatory Hurdles: Stringent approvals delays can impede new product launches.

3. Environmental Regulations: Stricter environmental standards could increase manufacturing costs.

4. Price Pressures: Competitive pricing, especially in commoditized segments, constrains profit margins.

5. Supply Chain Disruptions: Geopolitical tensions and pandemics impact raw material access and logistics.

What Are the Strategic Opportunities?

• Developing proprietary formulations with enhanced stability or bioavailability.
• Investing in sustainable sourcing and manufacturing processes.
• Expanding into aseptic packaging and delivery innovations.
• Focusing on geographic expansion in emerging markets.
• Acquiring or collaborating with regional manufacturing hubs.

Key Takeaways

• The electrolyte market for magnesium sulfate, potassium chloride, potassium phosphate, sodium chloride, and sodium phosphate is characterized by steady global growth driven by clinical and industrial demand.
• North American and Asia-Pacific markets are the dominant regions, with growth propelled by healthcare infrastructure expansion.
• Innovations in drug delivery, regulatory approval, and supply chain optimization will shape future market dynamics.
• Manufacturing and raw material supply are concentrated risks.
• Market growth will continue at a CAGR of approximately 4%–7% through 2027, reaching an estimated USD 6.2 billion.

FAQs

1. Which electrolyte has the largest market share? Sodium chloride leads in revenue due to its extensive use in saline solutions and industrial applications.

2. How does regulation impact market growth? Strict regulatory standards can delay product approvals, but also ensure quality, fostering credibility and market stability for approved formulations.

3. What is the impact of emerging markets? These markets contribute significantly to growth, offering manufacturing expansion opportunities and increasing treatment rates for electrolyte-related conditions.

4. Are there sustainability concerns? Yes. Stricter environmental policies influence manufacturing practices and raw material sourcing, potentially increasing costs.

5. What innovations are most likely to influence future growth? Delivery system improvements, bioavailability enhancements, and sustainable production practices are critical for expanding market share.

---

References

1. MarketWatch, “Electrolyte solutions market size,” 2023.
2. Grand View Research, “Global Electrolytes Market Insights,” 2022.
3. IQVIA, “Pharmaceutical R&D and Market Trends,” 2023.
4. U.S. FDA, “Regulatory Guidelines for Electrolyte Products,” 2022.
5. Pharma Intelligence, “M&A Trends in Inorganic Salt Markets,” 2023.